Akero Therapeutics Stock News

Here is how Akero Therapeutics, Inc. (AKRO) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.

Here is how Akero Therapeutics, Inc. (AKRO) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious me

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious meta

Steven Cohen (Trades, Portfolio), leader of Point72 Asset Management, disclosed earlier this week he upped his stake in Akero Therapeutics Inc. ( AKRO , Financial) by 25.25%.

Akero Therapeutics, Inc. (NASDAQ:AKRO) has earned a consensus recommendation of Buy from the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued []

Akero Therapeutics (NASDAQ: AKRO) recently received a number of ratings updates from brokerages and research firms: 11/16/2021 Akero Therapeutics was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They now have a $29.00 price target on the stock. According to Zacks, Akero Therapeutics Inc. is a clinical-stage []

SOUTH SAN FRANCISCO, Nov. 26, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic

SOUTH SAN FRANCISCO, Nov. 26, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic di

California State Teachers Retirement System grew its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) by 73.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 35,465 shares of the companys stock after acquiring an additional 14,976 shares during the quarter. California State Teachers Retirement System owned []

Akero Therapeutics (NASDAQ:AKRO) had its price target hoisted by Canaccord Genuity from $46.00 to $49.00 in a research note published on Monday, The Fly reports. They currently have a buy rating on the stock. Several other equities research analysts also recently issued reports on AKRO. Bank of America started coverage on Akero Therapeutics in a []

Akero Therapeutics (NASDAQ:AKRO) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. The brokerage presently has a $29.00 price objective on the stock. Zacks Investment Researchs target price suggests a potential upside of 13.86% from the companys []

The mean of analysts' price targets for Akero Therapeutics, Inc. (AKRO) points to a 91.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreeme

Akero Therapeutics (NASDAQ:AKRO) had its price objective decreased by equities research analysts at HC Wainwright from $64.00 to $62.00 in a report released on Monday, PriceTargets.com reports. The brokerage currently has a buy rating on the stock. HC Wainwrights price target would suggest a potential upside of 147.70% from the companys previous close. AKRO has []